| Lincoln Trail Behavioral Health System | |
|
7260 N Dixie Blvd Radcliff KY 40160-8599 | |
| (270) 351-9444 | |
| (270) 351-8980 |
| Full Name | Lincoln Trail Behavioral Health System |
|---|---|
| Speciality | Social Worker |
| Location | 7260 N Dixie Blvd, Radcliff, Kentucky |
| Authorized Official Name and Position | Steve Filton (SR VP CFO) |
| Authorized Official Contact | 6107683300 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lincoln Trail Behavioral Health System 3909 S. Wilson Rd. Radcliff KY 40160-8599 Ph: (270) 351-9444 | Lincoln Trail Behavioral Health System 7260 N Dixie Blvd Radcliff KY 40160-8599 Ph: (270) 351-9444 |
| NPI Number | 1851500466 |
|---|---|
| Provider Enumeration Date | 05/21/2007 |
| Last Update Date | 04/02/2020 |
| Certification Date | 04/02/2020 |
| Medicare PECOS PAC ID | 2062403017 |
|---|---|
| Medicare Enrollment ID | O20040519001214 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851500466 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| 106H00000X | Marriage & Family Therapist | (* (Not Available)) | Secondary |
| Provider Name | Ingrid Hertha Medley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952357774 PECOS PAC ID: 5395770325 Enrollment ID: I20050928001208 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Muhammad W Sajid |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1801825500 PECOS PAC ID: 3971537317 Enrollment ID: I20080820000532 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Sarwat N Mian |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1629186853 PECOS PAC ID: 8325102296 Enrollment ID: I20090122000136 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Angie L Walker |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1821174566 PECOS PAC ID: 2860659125 Enrollment ID: I20120130000406 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Arun Kaithi |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1851578579 PECOS PAC ID: 6305005828 Enrollment ID: I20120301000905 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Sufian Ahmad |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1821352824 PECOS PAC ID: 0244529873 Enrollment ID: I20160520000143 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Nicole Bailey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912445651 PECOS PAC ID: 6507092947 Enrollment ID: I20170403000183 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Amanda Medley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538620356 PECOS PAC ID: 3072855824 Enrollment ID: I20190429000451 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
| Provider Name | Sandra L Aubrey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538202817 PECOS PAC ID: 3971917287 Enrollment ID: I20210128000551 |
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
News Archive
Among 6- and 7-year-olds who were born extremely preterm-before the 28th week of pregnancy-those who had more than two hours of screen time a day were more likely to have deficits in overall IQ, executive functioning (problem solving skills), impulse control and attention, according to a study funded by the National Institutes of Health.
Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.
AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.
Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that, after numerous consultations with the Chinese government, its strategic partner, Medical Technologies Innovation Asia, Ltd., believes that Echo's locally produced needle-free CGM products will be designated as a Class 2 medical device.
Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.
› Verified 1 days ago
Family Dynamics Behavioral Health Care Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 299 W Lincoln Trail Blvd, Suite 5, Radcliff, KY 40160 Phone: 270-351-4880 Fax: 270-351-4881 | |
Serenity Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 663 N Dixie Blvd Ste K, Radcliff, KY 40160 Phone: 229-343-1822 Fax: 502-430-2416 | |
Universal Concepts Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 241 Oak Ridge Dr, Radcliff, KY 40160 Phone: 270-351-4859 | |
E.l.y. Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 645 Knox Blvd Ste A, Radcliff, KY 40160 Phone: 270-272-2046 | |
Yellow Sage Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 562 N Dixie Blvd Ste B4, Radcliff, KY 40160 Phone: 270-317-1318 | |
Glimmer Of Hope, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 W Lincoln Trail Blvd, Radcliff, KY 40160 Phone: 270-351-3192 Fax: 270-351-5499 | |
Lincoln Trail Behavioral Health System Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 3909 S Wilson Rd, Radcliff, KY 40160 Phone: 270-351-9444 Fax: 270-351-0400 |